相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1855
已完成
1
100.0%
暂无批准数据
- A Penn State-led study found that proteins containing an entanglement in their native structure are 93% more likely to be tagged for degradation than proteins without one. - About a third of entangled proteins evade the cellular quality control system despite high misfolding rates, potentially accumulating and disrupting protein homeostasis. - Computer simulations showed tagged entangled proteins are four times more likely to misfold than untagged proteins without an entanglement. - The findings, published in Nature Communications, could inform new origins and treatments for diseases such as Alzheimer's and Huntington's.
- A Penn State-led team developed STREAM, a platform that rapidly grows and analyzes bacteria to identify bloodstream infection pathogens in as little as seven hours, versus two to seven days for conventional culturing. - The approach integrates single-cell imaging, computer algorithms, and antibiotic susceptibility testing to simultaneously name the pathogen and recommend effective antibiotics before sepsis develops. - Testing on about 100 positive blood samples showed comprehensive diagnosis within hours, though a 4% "very major error" rate and challenges with pre-treated patients remain hurdles before clinical use. - The framework offers a scalable foundation that could expand to fungal infections and aims to curb worsening antibiotic resistance through faster, more targeted treatment.
- Penn State researchers developed a biomimetic zona pellucida (BZP) hydrogel coating that shields transplanted insulin-producing islets from immune attack without immunosuppressants. - In diabetic mice, BZP-coated islets restored healthy blood sugar levels within one week and kept most animals diabetes-free for more than 100 days. - The ultrathin 20-micrometer coating mimics the natural zona pellucida of human egg cells, remaining permeable enough to release insulin while concealing cells from the immune system. - The findings, published in Nature Biomedical Engineering, could support future cell therapy platforms for diabetes and other diseases after further research and clinical trials.
- A phase II randomized clinical trial led by Penn State and USC researchers demonstrated that targeted therapy for the less-impaired arm significantly improved movement and control in chronic stroke survivors with severe paralysis. - The study of 53 participants showed that training the "good" arm resulted in 12% faster completion of dexterity tests, with improvements persisting for at least six months after therapy ended. - This first-of-its-kind evidence-based intervention challenges traditional stroke rehabilitation by addressing the often-overlooked 10-25% loss of motor coordination in the less-impaired arm. - The findings, published in JAMA Neurology, could meaningfully enhance quality of life and reduce caregiver burden for stroke survivors who rely on their functional arm for daily tasks.
- Penn State researchers discovered that two FDA-approved prostate cancer drugs, apalutamide and finasteride, effectively suppressed acute myeloid leukemia progression in both male and female mice and patient-derived AML cells. - The study revealed that androgen signaling pathways, previously unexplored in leukemia, play a crucial role in AML development through dihydrotestosterone and androgen receptor interactions. - This research identifies androgen receptors as a novel therapeutic target for AML treatment, potentially offering new options for patients who are resistant to traditional chemotherapy, radiotherapy, and stem cell transplantation. - The findings, published in Blood Advances, represent a significant breakthrough as AML treatments have remained largely unchanged despite high relapse rates in patients.
- Researchers at Penn State and Hebei University of Technology developed a breath sensor that successfully distinguished between type 2 diabetes patients and healthy individuals by detecting acetone levels in exhaled breath. - The sensor demonstrated high sensitivity, detecting acetone at concentrations as low as 4 parts per billion with a 20-second response time, and showed correlation with participants' blood sugar levels. - Testing involved 51 people with type 2 diabetes and 20 healthy volunteers, with the sensor responding differently to diabetic patients' breath samples collected in aluminum foil bags. - The technology could address a critical gap in diabetes screening, as approximately 20% of the 37 million adults with diabetes in the U.S. remain undiagnosed due to barriers with current blood-based testing methods.
- The FDA has approved EXZOLT (fluralaner oral solution), the first systemic oral treatment for northern fowl mites in chickens, offering a novel alternative to traditional topical sprays. - Penn State researchers conducted pivotal efficacy studies showing over 90% reduction in mite populations, demonstrating the treatment's effectiveness in both broiler breeders and layer chickens. - The innovative water-administered treatment targets the parasite's nervous system while maintaining a zero-day egg withdrawal period and 11-day meat withdrawal period. - EXZOLT addresses significant economic losses in poultry operations caused by northern fowl mites, which reduce weight gain, egg quality, and production in affected birds.
